Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urinary Antigen Assay Detects Legionella

By LabMedica International staff writers
Posted on 16 Feb 2012
An antigen test had been evaluated for its ability to diagnose Legionnaires’ disease (LD) using urine samples. More...


Laboratory diagnosis of Legionella pneumophila infections in patients with pneumonia is based on culture, serological testing, molecular testing, and detection of soluble L. pneumophila antigen in urine.

Scientists at the Regional Laboratory of Public Health (Haarlem, The Netherlands) tested frozen urine samples from a well-described sample of patients with and without LD. Urine samples were collected between 1997 and 2010 and were stored at -70 °C until processing was performed. These included 58 urine samples from 58 patients with LD. The specificity of the test was determined by using urine samples collected from 38 patients with respiratory tract infections other than Legionella infections.

The SD Bioline Legionella Urinary Antigen test (Standard Diagnostics Inc., Kyonggi-do, Korea) was compared with those obtained by the BinaxNOW Legionella Urinary Antigen enzyme immunoassay (EIA) (Galway, Ireland). A total of 96 samples were tested with the SD Bioline and BinaxNOW test. SD Bioline test was positive for 46/58 samples with sensitivity of the assay estimated as 79%. The BinaxNOW urinary antigen test was positive 47/58, with a sensitivity of 81%. These results were obtained after 15 minutes of incubation. The difference in sensitivity between SD Bioline test and BinaxNOW is comparable. Both tests were negative in the 38 samples from the non-Legionella patients giving a specificity of 100% for both assays.

LD is an acute pneumonia caused by Legionella species, which are non-spore-forming Gram-negative rods. L. pneumophila serogroup 1 accounts for more than 90% of human infections and is the most important etiological agent of LD. It is estimated that 8,000-18,000 cases of Legionnaires' disease occur in the USA each year. The authors concluded that the findings of the evaluation indicate that the SD Bioline test is both sensitive and specific and could be a good alternative for the detection of L. pneumophila serogroup 1 antigen in urine from patients suspected of having LD. The study was published in the January 2012 edition of the Journal of Infection.

Related Links:
Regional Laboratory of Public Health
Standard Diagnostics Inc.
BinaxNOW


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.